Gastroenterology
Latest news
363 articles · 20 / page
Revisiting Rehydration Strategies in Severe Acute Malnutrition with Gastroenteritis: Intravenous Versus Oral Approaches
A recent trial assessing intravenous versus oral rehydration in children with severe acute malnutrition and gastroenteritis found no mortality difference at 96 hours, challenging fears of fluid overload and supporting cautious consideration
Primary Sclerosing Cholangitis in a 45-Year-Old Male: A Case Report
A 45-year-old male presents with cholestatic liver enzyme elevation and pruritus, diagnosed with primary sclerosing cholangitis confirmed by imaging and liver biopsy. Clinical management and prognosis are discussed.
Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults
Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.
Decoding the Role of Reflux Secondary Bile Acids in Barrett’s Esophagus: Microbiome and Transcriptome Insights
This study reveals that elevated reflux secondary bile acids in Barrett’s esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.
The Withdrawal of OCALIVA: Impact and Implications for Primary Biliary Cholangitis Treatment
Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.
Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis
AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this
Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis
The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.
Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
Why Losing Weight Can Worsen Fatty Liver Disease: The Crucial Role of Balanced Nutrition
Losing weight doesn’t always mean improving fatty liver disease. Discover why strict diets lacking essential proteins can worsen liver health and learn practical dietary strategies to manage and reverse fatty liver effectively.
Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity
Intraduodenal calcium at doses up to 1000 mg amplifies the anorexigenic effects of L-tryptophan by boosting gut hormones CCK, GLP-1, and PYY, reducing energy intake in obese males, highlighting a novel adjunctive approach for appetite regul
Enhanced Adenoma Detection in Water Exchange Colonoscopy Using AI: Insights from a Two-Center Randomized Trial
A multicenter trial demonstrated that integrating AI-based computer-aided detection with water exchange colonoscopy significantly increases adenomas per colonoscopy without prolonging procedure time or increasing non-neoplastic lesion detec
AI-Assisted Optical Diagnosis in Colonoscopy: Ensuring Safety While Reducing Unnecessary Polypectomies
A randomized trial demonstrates that leaving small non-neoplastic colorectal polyps in situ with AI-assisted optical diagnosis is as safe and effective as systematic removal, supporting less invasive colonoscopy strategies.
Optimizing Colorectal Cancer Screening Outreach for Adults Aged 45-49: Insights From a Large-Scale Randomized Trial
A large UCLA Health randomized clinical trial found that usual care via mailed FIT outreach outperformed active choice strategies in colorectal cancer screening uptake among adults aged 45 to 49 years, highlighting the challenges in engagin
Fatty Liver Disease: Should You Cut Back on Carbs or Meat? The Science Behind Dietary Choices
Explore how carbohydrates, proteins, and fats affect fatty liver disease and learn evidence-based dietary and lifestyle recommendations to manage and reverse this common condition.
Linarin as a Multifaceted Therapeutic Agent for NAFLD: Modulation of PI3K/Akt/mTOR, Autophagy, and Gut Microbiota
Linarin shows promise in mitigating NAFLD by enhancing autophagy via PI3K/Akt/mTOR inhibition, reducing inflammation, and restoring gut microbiota balance, alongside activating the PDE4D/cAMP/PKA/CREB pathway to improve hepatic lipid metabo
Browse by specialty
Open language-specific specialty feeds and department pages.